Download “Market Access and Reimbursement of Novel Therapeutics” research report for insights on reimbursement decisions at health insurers
Biotech and pharmaceutical companies bringing novel therapeutics to market should be prepared to assuage concerns among payers that these often high-cost drugs are worth their hefty price tags, according to a new survey of health insurance executives by the Center for Connected Medicine (CCM).
The research was conducted in partnership with KLAS Research and surveyed representatives of a wide range of payer organizations, including large national insurers, provider-sponsored health plans, and small regional payers. Download the report from link at the top of the page.
The survey shows payers were nearly unanimous in calling the growing cost of novel therapeutics, such as cell and gene therapies to treat rare and previously untreatable diseases, a “high” concern for their organizations.